Table 3.
Effects of D2/D3R antagonists on psychostimulant abuse-related behaviors.
| Model | Treatment (D3:D2R selectivity) | Dose of treatment | Effect (Psychostimulant dose); Species; Schedule; Further comments | Reference |
|---|---|---|---|---|
| Cocaine: SA maintenance on FR1 or FR2 | YQA14 (167-fold) | 6.25–25 mg/kg, IP | ↓ ascending/peak dose (0.03–0.125 mg/kg, IV); rats; FR2 | (Song et al., 2012a) |
| 25 mg/kg, IP | ↓ descending limb (0.25 mg/kg, IV); rats; FR2 | |||
| 25–50 mg/kg, IP | ↓ descending limb (1 mg/kg, IV); mice; FR1; Ø in D3R knockout mice | |||
| SB-277011A (93-fold) | 5–20 mg/kg, IP or PO | Ø descending limb (0.25 mg, IV); rats; FR1 | (Gál and Gyertyán, 2003; Gyertyan and Saghy, 2007) | |
| 0.3–30 mg/kg, IP | Ø descending limb (0.75 mg/kg, IV); rats; FR1 | (Di Ciano et al., 2003b; Xi et al., 2005) | ||
| 100 mg/kg, IP | ↓ descending limb (1 mg/kg, IV); mice; FR1; Ø in D3R knockout mice | (Song et al., 2012a) | ||
| 12.5–25 mg/kg, IP | ↓ ascending/peak dose (0.03-0.125 mg/kg, IV); rats; FR2 | |||
| ↓ descending limb (0.25 mg/kg, IV); rats; FR2 | ||||
| NGB-2904 (56-fold) | 0.1–10 mg/kg, IP | Ø descending limb (0.5 mg/kg, IV); rats; FR2 | (Xi et al., 2006) | |
| L-745,829 (41-fold) | 0.1–10 mg/kg, IP | Ø descending limb (1 mg/kg, IV); rats; FR1 | (Caine et al., 2002) | |
| 5.6 mg/kg, IP | Ø ascending/descending limb (0.032–3.2 mg/kg, IV); rats; FR1 | |||
| S33138 (25-fold) | 2.5 mg/kg, PO | ↑ descending limb (0.5 mg/kg, IV); rats; FR2 | (Peng et al., 2009) | |
| 5 mg/kg, PO | ↓ descending limb (0.5 mg/kg, IV); rats; FR2 | |||
| Eticlopride (0.44-fold) | 0.1–0.18 mg/kg, IP | ↑ descending limb (1 mg/kg, IV); mice; FR1; Ø in D2R knockout mice | (Caine et al., 2002) | |
| Methamphetamine: SA maintenance on FR1 or FR2 | PG-01037 (133-fold) | 3–30 mg/kg, IP | Ø descending limb (0.05 mg/kg, IV); rats; FR2 | (Higley et al., 2011b) |
| 8–32 mg/kg, SC | Ø descending limb (0.05 mg/kg, IV); rats; FR1; long and short access | (Orio et al., 2010) | ||
| SB-277011A | 6–24 mg/kg, IP | Ø descending limb (0.05 mg/kg, IV); rats; FR2 | (Higley et al., 2011a) | |
| Cocaine: SA maintenance on other schedules | YQA14 | 1.04–12.5 mg/kg, IP | ↓ (0.5 mg/kg, IV); rats; PR | (Song et al., 2012a) |
| 50 mg/kg, IP | ↓ (1 mg/kg, IV); mice; PR; Ø in D3R knockout mice | |||
| PG-01037 | 30 mg/kg, IM | Ø (0.03–0.3 mg/kg, IV); monkeys; 2nd order schedule | (Achat-Mendes et al., 2010a) | |
| 100 mg/kg, IM | Ø (0.1 mg/kg, IV); monkeys; 2nd order schedule | |||
| SB-277011A | 24 mg/kg, IP | ↓ peak/descending limb (0.125–0.25 mg/kg/inf, IV); rats; FR10 | (Xi et al., 2005) | |
| 12–24 mg/kg, IP | ↓ (0.5 mg/kg, IV); rats; PR | |||
| 50 mg/kg, IP | ↓ (1 mg/kg, IV); mice; PR; Ø in D3R knockout mice | (Song et al., 2012b) | ||
| 20–30 mg/kg, IP | ↓ descending limb (0.75 mg/kg, IV); rats; 2nd order schedule | (Di Ciano et al., 2003b) | ||
| NGB-2904 | 1–5 mg/kg, IP | ↓ (0.5 mg/kg, IV); rats; PR | (Xi et al., 2006) | |
| 1–5.6 mg/kg, IV | Ø (1 mg/kg, IV); monkeys; 2nd order schedule | (Martelle et al., 2007) | ||
| WC10 (42-fold) | 10 mg/kg, IP | ↓ ascending/descending limb (0–0.375 mg/kg, IV); rats; VI60s | (Cheung et al., 2012) | |
| Eticlopride | 0.1–0.32 mg/kg, IP | ↓ ascending limb (0.1–0.32 mg, IV); rats; FR5 | (Barrett et al., 2004) | |
| 0.1 mg/kg, IP | ↑ descending limb (1 mg, IV); rats; FR5 | |||
| Methamphetamine: SA maintenance on other schedules | PG-01037 | 10–30 mg/kg, IP | ↓ (0.05 mg/kg, IV); rats; PR | (Higley et al., 2011b) |
| 32 mg/kg, IP | ↓ (0.05 mg/kg, IV); rats; PR; long but not short access | (Orio et al., 2010) | ||
| SB-277011A | 12–24 mg/kg, IP | ↓ (0.05 mg/kg, IV); rats; PR | (Higley et al., 2011a) | |
| Cocaine seeking, early abstinence (<48h) | SB-277011A | 10–30 mg/kg, IP | ↓ before 1st reinforcer; rats; 2nd order schedule | (Di Ciano et al., 2003b) |
| 4 μg/side, intra-BLA but not dSt or NAc shell | ↓ before 1st reinforcer; rats; 2nd order schedule | (Di Ciano, 2008) | ||
| Cocaine seeking, protracted abstinence | SB-277011A | 5–20 mg/kg, IP or PO | ↓ rats; response-contingent cues | (Gyertyan and Saghy, 2007; Xi et al., 2005) |
| 10–30 mg/kg, IP | ↓ rats; discriminative cues | (Cervo et al., 2007b) | ||
| NGB-2904 | 5 mg/kg, IP | ↓ rats; response-contingent cues | (Gilbert et al., 2005) | |
| Raclopride (0.79-fold) | 1 mg/kg, SC | ↓ rats; discriminative cues | (Cervo et al., 2003a) | |
| Methamphetamine seeking* | PG-01037 | 10–30 mg/kg, IP | ↓ rats; response-contingent cues | (Higley et al., 2011b) |
| Cocaine-primed reinstatement of cocaine seeking* | PG-01037 | 30 mg/kg, IM | ↓ (prime: 0.3–1 mg/kg, IV); monkeys; cues on a 2nd order schedule | (Achat-Mendes et al., 2010a) |
| SB-277011A | 6–12 mg/kg, IP | ↓ (prime: 1 mg/kg, IV); rats | (Vorel et al., 2002) | |
| NGB-2904 | 1–5 mg/kg, IP | ↓ (prime: 10 mg/kg, IP); rats | (Xi et al., 2006) | |
| S33138 | 0.625–2.5 mg/kg, PO | ↓ (prime: 10 mg/kg, IP); rats | (Peng et al., 2009) | |
| Sulpiride (0.13-fold) | 2 μg/side, intra-NAc shell but not core | ↓ (prime: 10 mg/kg, IP); rats | (Anderson et al., 2006) | |
| Methamphetamine-primed reinstatement of methamphetamine seeking* | SB-277011A | 12–24 mg/kg, IP | ↓ (prime: 1 mg/kg, IP); rats | (Higley et al., 2011a) |
| Stress-primed reinstatement of cocaine seeking* | SB-277011A | 12 mg/kg, IP | ↓ rats; footshock stress-prime | (Xi et al., 2004) |
| 1.5 μg/side, intra-NAc but not dSt | ↓ rats; footshock stress-prime |
Table key. ↑: increased compared with control. ↓: decreased compared with control. Ø: no effect compared with control. SA: self-administration. FR: fixed ratio schedule of reinforcement. PR: progressive ratio schedule of reinforcement. VI: variable interval schedule of reinforcement. BLA: Basolateral amygdala. CeA: Central amygdala. NAc: Nucleus accumbens. dSt: Dorsal striatum.
*
: tests carried out after protracted abstinence (<48h).